Published in Obesity and Diabetes Week, December 1st, 2003
Patient enrollment is commencing in the trial entitled: "Prospective Phase I/II Safety Study of Encapsulated Isolated Primary Human Pancreatic Islet Transplantation with Low Dose Short Term Immune Suppression in Patients with Type 1 Diabetes Mellitus."
The study is being conducted at the Toronto General Hospital (TGH) of the University Health Network in collaboration with TGH's Multi Organ Transplant (MOT) Program (www.torontotransplant.org). The study is approved by Health...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week